TMS Co Ltd
TSE:4891
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
151
337
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
TMS Co Ltd
Cash & Cash Equivalents
TMS Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TMS Co Ltd
TSE:4891
|
Cash & Cash Equivalents
¥3.4B
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Cash & Cash Equivalents
¥16.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
|
PeptiDream Inc
TSE:4587
|
Cash & Cash Equivalents
¥50.4B
|
CAGR 3-Years
60%
|
CAGR 5-Years
43%
|
CAGR 10-Years
31%
|
|
|
Takara Bio Inc
TSE:4974
|
Cash & Cash Equivalents
¥38B
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
5%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Cash & Cash Equivalents
¥15.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
29%
|
CAGR 10-Years
26%
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Cash & Cash Equivalents
¥5.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
TMS Co Ltd
Glance View
TMS Co., Ltd. engages in the research and development of pharmaceutical products and medical devices. The company is headquartered in Fuchu-Shi, Tokyo-To and currently employs 8 full-time employees. The company went IPO on 2022-11-22. The firm conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
See Also
What is TMS Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.4B
JPY
Based on the financial report for Feb 29, 2024, TMS Co Ltd's Cash & Cash Equivalents amounts to 3.4B JPY.
What is TMS Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
46%
Over the last year, the Cash & Cash Equivalents growth was -4%. The average annual Cash & Cash Equivalents growth rates for TMS Co Ltd have been 46% over the past three years .
You don't have any saved screeners yet
